Tag:
Kalydeco
Latest Headlines
Latest Headlines
Support seen for U.S. plan to speed nods for 'breakthrough' drugs
This year the agency and U.S. lawmakers appear to be supportive of a plan that would help pharma groups race to the market with breakthrough drugs.
UPDATED: Vertex sizzles with upbeat PhII data on combo therapy for cystic fibrosis
The data indicate that Vertex might have a remedy for treating a large number of the 70,000 people worldwide with CF.
U.K. CF gene therapy trials to test inhaled and viral delivery options
A cadre of U.K. researchers will begin a mid-stage trial later this month for a cystic fibrosis gene therapy delivered to the lungs with a nebulizer. They'll also begin a laboratory trial using a more advanced version of the same drug designed to ride in a modified virus to reach its target.
One father's heartbreak inspired a $250M quest for a cure
How one father's loss turned into gain for cystic fibrosis patients and Vertex Pharmaceuticals ( $VRTX ): After the death of his son, Boston businessman Joe O'Donnell spent years raising $250 million
One father's heartbreak inspired a $250M quest for a cure
Every new drug ever approved involved years of work by dedicated teams of investigators. In the case of the new cystic fibrosis drug Kalydeco from Vertex ( $VRTX ), the story also includes Boston
Kalydeco ranks among 12 priciest drugs in U.S.
Last week, Vertex Pharmaceuticals ( $VRTX ) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's cause, rather than just its symptoms. The price tag: $294,000. But as
How do the 12 priciest drugs in the U.S. stack up?
Last week, Vertex Pharmaceuticals ( $VRTX ) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's cause, rather than just its symptoms. The price tag: $294,000. But as
Vertex backs up pricey new CF drug with co-pay help
Vertex Pharmaceuticals ( $VRTX ) achieved another major milestone with FDA's approval of its cystic fibrosis therapy Kalydeco. The "breakthrough" product is the first to address CF's...
UPDATED: Vertex nabs expedited FDA OK on breakthrough CF drug
Vertex Pharmaceuticals ( $VRTX ) is no longer a one-trick biotech company. The FDA issued an early approval today for Kalydeco (ivacaftor), a new drug that promises to strengthen the lungs and ease
